Drugs / ISB 1342
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03309111 | Oct 2017 → Dec 2023 | refractory plasma cell neoplasm | Ichnos Sciences SA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-12-12 | Ichnos Sciences SA | Results Ichnos Sciences Delivers Strong Evidence for its Trio of Oncology Assets at ASH 2023 Annual Meetings iginnovate.com ↗
The studies showcased encouraging safety profiles, dose-dependent pharmacokinetics, and efficacy signals, marking significant progress in the fight against relapsed or refractory multiple myeloma. |
| 2022-12-12 | Ichnos Sciences SA | Results Ichnos Sciences Presents Data Supporting Three Oncology Assets at ASH 2022 Annual Meeting iginnovate.com ↗
Ichnos presentations include clinical and preclinical data on ISB 1342 (CD38xCD3), ISB 1442 (CD38xCD47) and an oral session on ISB 2001, its first TREAT ™ trispecific (BCMAxCD38xCD3) antibody |
| 2021-06-04 | Ichnos Sciences SA | Results Ichnos Sciences Presents Preclinical Data Confirming Potential for ISB 1342 in Relapsed/Refractory Multiple Myeloma at 2021 ASCO Annual Meeting iginnovate.com ↗
Ichnos’ data demonstrate the ability of ISB 1342 to redirect T lymphocytes against tumor cells expressing varying levels of CD38 in preclinical in vitro and in vivo potency models. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-12-12 | Ichnos Sciences SA | Ichnos Sciences Delivers Strong Evidence for its Trio of Oncology Assets at ASH 2023 Annual Meetings iginnovate.com ↗ |
| 2022-12-12 | Ichnos Sciences SA | Ichnos Sciences Presents Data Supporting Three Oncology Assets at ASH 2022 Annual Meeting iginnovate.com ↗ |
| 2021-06-04 | Ichnos Sciences SA | Ichnos Sciences Presents Preclinical Data Confirming Potential for ISB 1342 in Relapsed/Refractory Multiple Myeloma at 2021 ASCO Annual Meeting iginnovate.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISB-1342 | “ISB-1342 is CD38 x CD3 BEAT® 1.0 bispecific antibody.” NCT03309111 ↗ |
| Route | Intravenous | “ISB 1342 is administered by intravenous (IV) infusion” NCT03309111 ↗ |